Sihuan Pharmaceutical (HKG:0460) non-wholly owned subsidiaries Huisheng Biopharmaceutical and Meiyan Space signed an exclusive authorization cooperation deal for Huisheng's semaglutide injection.
Meiyan Space, Sihuan's medical aesthetics unit, will have exclusive engagement rights in mainland China for the weight loss drug, the filing said.